Yes PAR has 180 days exclusivity on the 25 and 35 mg doses of focalin. IPCI benefits accordingly although the relative market sales of these two doses isn't huge as noted in the report.
Mopar....what I found strange in reading the report you attached, was they are increasing their revenue projections from 4 million to 12 million yet they only mentioned the launch of the 25 and 35 mg Focalin. PAR did receive approval for all the remaining doses. the fact the report failed to mention.
So I wonder if they are expecting that 12 million from just the announced 2 additional doses? if so that would need to be increased again when they do launch the remaining doses.
my personal opinion the 12 million would need to come for all doses being launched. seeing how the 2 doses they had launched was only bringing in around 3 million a year. I cant see where these wo new doses would garner an additional 9 million. I guess its possible though with exclusivity.
anyone else want to weigh in? because, again the launch of the additional doses would significantly change these projections they just released.
News 
Market Data 
Discover 
AI
